ARCHIVES

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

DCPC Developing Hispanic Cancer Control Intervention Program Concept

August 12, 1988

SWOG Trial Reports Longest Survival To Date For NSCLC

June 29, 2001

Zometa Can Reduce Risk Of Skeletal-Related Events

August 26, 2011

NIH Funding Opportunities Listed

March 13, 2009

In Brief: Cancer Act, Accelerated Progress, ACS President Says; Scanners Scapegoats, EMI Chief Claimes

April 7, 1978

Genetic Testing: No Easy Answers To Public Questions

May 15, 1998